Sugi Predict

Sugi Predict / Compounds / SCHEMBL4433688

SCHEMBL4433688

SCHEMBL4433688

CSc1ncc2cc(-c3cc(NC(=O)Nc4cnn(C(C)(C)C)c4C)c(F)cc3Cl)c(=O)n(C)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 3/20 0.46
▸ BRAF P15056 3/20 0.46
▸ FGFR1 P11362 6/20 0.36
▸ SRC P12931 8/20 0.35
▸ ABL1 P00519 8/20 0.35
▸ PDGFRB P09619 7/20 0.35
▸ PDGFRA P16234 7/20 0.35
▸ MAPK14 Q16539 6/20 0.35
▸ EGFR P00533 4/20 0.35
▸ STK4 Q13043 2/20 0.35
▸ STK3 Q13188 2/20 0.35
▸ SIK2 Q9H0K1 2/20 0.35
▸ STK26 Q9P289 2/20 0.35
▸ STK24 Q9Y6E0 2/20 0.35
▸ ACVR1 Q04771 2/20 0.35
▸ PKMYT1 Q99640 2/20 0.35
▸ STAT5A P42229 1/20 0.35
▸ KDR P35968 2/20 0.34
▸ MAP2K2 P36507 2/20 0.34
▸ MAP2K1 Q02750 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5061820 0.92 BRAF (0.55) RAF1BRAFFGFR1SRCABL1
SCHEMBL5061874 0.91 RAF1 (0.45) RAF1BRAFFGFR1SRCABL1
SCHEMBL4565897 0.88 BRAF (0.60) RAF1BRAFFGFR1SRCABL1
SCHEMBL4427764 0.88 RAF1 (0.45) RAF1BRAFFGFR1SRCABL1
SCHEMBL5061497 0.84 BRAF (0.55) RAF1BRAFFGFR1SRCABL1
SCHEMBL4426093 0.83 MAPK14 (0.46) RAF1BRAFFGFR1ABL1MAPK14
SCHEMBL5057666 0.82 BRAF (0.46) RAF1BRAFFGFR1PDGFRBPDGFRA
SCHEMBL5065211 0.82 BRAF (0.49) RAF1BRAFFGFR1SRCABL1
SCHEMBL5065266 0.81 BRAF (0.46) RAF1BRAFFGFR1SRCABL1
SCHEMBL4420381 0.81 BRAF (0.54) RAF1BRAFFGFR1SRCABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 — — US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 — — EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 — — US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 RAF1 3/4885BRAF 1/4885FGFR1 577/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 RAF1 3/4885BRAF 1/4885FGFR1 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.